|
|Section2= |Section3= }} Orteronel (TAK-700) is a non-steroidal antiandrogen that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals.〔(Millennium and Takeda Announce Advancement of Prostate Cancer Program ), Millennium Pharmaceuticals〕 It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result.〔(【引用サイトリンク】 author = MarketWatch )〕 Orteronel is an androgen biosynthesis inhibitor. It selectively inhibits the enzyme CYP17A1 which is expressed in testicular, adrenal, and prostatic tumor tissues. CYP17 catalyzes two sequential reactions: (a) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by its 17α-hydroxylase activity, and (b) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by its 17,20-lyase activity. DHEA and androstenedione are androgens and precursors of testosterone. Inhibition of CYP17 activity thus decreases circulating levels of testosterone. ==See also== * Abiraterone acetate * VT-464 * Galeterone * Cyproterone acetate * Ketoconazole * Enzalutamide * Apalutamide * EPI-001 * ODM-201 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「orteronel」の詳細全文を読む スポンサード リンク
|